journal article·2024-11-13

Small-Molecule Therapeutics Achieve Multiple Mechanism-Mediated Sensitizations of Colorectal Cancer to Immune Checkpoint Blockade via Neutrophil Micropharmacies

Xiuqi Li, Xuwentai Liu, Meng Wang, Xinyi Zhang, Ziyao Zhang, Lingjing Xue, Qianqian Xu, Juanjuan Ye, Meixi Hao, Can Zhang

Nano Letters· Volume 24· Issue 45
Publisher page

Abstract

Immune checkpoint blockade (ICB) therapy has been approved for colorectal cancer (CRC). However, response rates are variable and often <50%. The low tumor immunogenicity and immunosuppressive tumor microenvironment (TME) jointly contribute to this suboptimal response rate. This study confirmed the potential of combining immunogenic cell death (ICD) inducer irinotecan (IRI) and transforming growth factor-β (TGF-β) inhibitor galunisertib (GAL) to improve tumor immunogenicity and remodel the immunosuppressive TME. Moreover, to ameliorate the in vivo delivery barriers associated with small molecules, neutrophil micropharmacies (NOG) were developed for the codelivery of IRI and GAL, which loaded the commercial liposome formulation of IRI (ONIVYDE, ONI) intracellularly and conjugated the pH-responsive GAL liposome (GLP) on the cell surface. This neutrophil-based formulation resulted in a >4-fold increase in the ratios of the amount of both IRI and GAL accumulated in tumors to the dosage administration, effectively achieving multiple mechanism-mediated sensitization of CRC to ICB therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immune cells in cancer · Cancer Immunotherapy and Biomarkers · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Natural Medicines, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 211198, China

Chongqing Innovation Institute of China Pharmaceutical University, Chongqing 401135, China

Funding

State Key Laboratory of Natural Medicines · Natural Science Foundation of Jiangsu Province · Double First Class University Plan · Fundamental Research Funds for the Central Universities · National Natural Science Foundation of China · Postgraduate Research & Practice Innovation Program of Jiangsu Province · Technology innovation project of Nucleic acid drug from National Center of Technology Innovation for Biopharmaceuticals

References (43)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1038/s41575-019-0189-810.1038/s41575-019-0189-8 ↗
3. 10.1016/S0140-6736(19)32319-010.1016/S0140-6736(19)32319-0 ↗
4. 10.1126/science.aaa817210.1126/science.aaa8172 ↗
5. 10.1038/s41392-023-01522-410.1038/s41392-023-01522-4 ↗
6. 10.1038/s41575-019-0126-x10.1038/s41575-019-0126-x ↗
7. 10.1158/1078-0432.CCR-21-055710.1158/1078-0432.CCR-21-0557 ↗
8. 10.1056/NEJMoa201769910.1056/NEJMoa2017699 ↗
9. 10.1016/S1470-2045(17)30422-910.1016/S1470-2045(17)30422-9 ↗
10. 10.1056/NEJMc171344410.1056/NEJMc1713444 ↗
11. 10.7554/eLife.4902010.7554/eLife.49020 ↗
12. 10.1093/annonc/mdz13410.1093/annonc/mdz134 ↗
13. 10.1038/s41573-018-0007-y10.1038/s41573-018-0007-y ↗
14. 10.1016/j.immuni.2015.11.02410.1016/j.immuni.2015.11.024 ↗
15. 10.1038/nrc338010.1038/nrc3380 ↗
16. 10.1038/s41590-022-01132-210.1038/s41590-022-01132-2 ↗
17. 10.1016/j.phrs.2019.10439810.1016/j.phrs.2019.104398 ↗
18. 10.1093/jnci/djx25710.1093/jnci/djx257 ↗
19. 10.3109/1547691X.2012.69354710.3109/1547691X.2012.693547 ↗
20. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
21. 10.1016/S0092-8674(00)00121-510.1016/S0092-8674(00)00121-5 ↗
22. 10.1038/ni.386810.1038/ni.3868 ↗
23. 10.1038/nature0875010.1038/nature08750 ↗
24. 10.1016/j.immuni.2015.04.01210.1016/j.immuni.2015.04.012 ↗
25. 10.1038/nature2549210.1038/nature25492 ↗
26. 10.1038/nature2550110.1038/nature25501 ↗
27. 10.4172/2161-0495.19610.4172/2161-0495.196 ↗
28. 10.1080/00498254.2017.132313710.1080/00498254.2017.1323137 ↗
29. 10.1016/j.cell.2020.10.00310.1016/j.cell.2020.10.003 ↗
30. 10.1038/s41573-019-0054-z10.1038/s41573-019-0054-z ↗
31. 10.1038/nri339910.1038/nri3399 ↗
32. 10.1038/nrc.2016.5210.1038/nrc.2016.52 ↗
33. 10.1002/ijc.2855110.1002/ijc.28551 ↗
34. 10.1016/j.ccell.2019.08.00310.1016/j.ccell.2019.08.003 ↗
35. 10.1016/j.ejca.2005.07.01710.1016/j.ejca.2005.07.017 ↗
36. 10.1038/nnano.2017.5410.1038/nnano.2017.54 ↗
37. 10.1002/adma.20180593610.1002/adma.201805936 ↗
38. 10.1002/smll.20180419110.1002/smll.201804191 ↗
39. 10.1021/acsnano.2c1176410.1021/acsnano.2c11764 ↗
40. 10.1016/j.jconrel.2023.05.03710.1016/j.jconrel.2023.05.037 ↗
41. 10.2147/OTT.S10558710.2147/OTT.S105587 ↗
42. 10.1038/s41551-024-01180-z10.1038/s41551-024-01180-z ↗
43. Xu G. · Clin. Cancer Res. · 2002 · 8 · 2605